Spotlight On

NSCLC

More in NSCLC

Treatment of Oligometastatic EGFR-Mutant Lung Cancer

More research needed on role of local therapy in new era of treatment

Nov 22, 2024
A computer rendering of a transparent body with the lungs and lung cancer highlighted.
Does an Additional First-Line Option Alter Approach in EGFR-Mutant NSCLC?

The approval of lazertinib/amivantamab gives clinicians one more option

Nov 01, 2024
A computer rendering of lung cancer.
Taking on Acquired Resistance in EGFR-Mutant NSCLC

TKIs are the first-line of defense, but "the more options we have the better," expert says

Nov 01, 2024
A computer rendering of human cell membrane showing HER3 bound to an epidermal growth factor receptor molecule.